Synergistic effects of COVID-19 and Pseudomonas aeruginosa in chronic obstructive pulmonary disease: a polymicrobial perspective

• Published in: Molecular and cellular biochemistry Vol. 479; no. 3; pp. 591 - 601
• Main Authors: Bajire, Sukesh Kumar, Shastry, Rajesh P.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2024; Springer; Springer Nature B.V
• Subjects: Biochemistry; Biomedical and Life Sciences; Bitolterol; Bronchitis; Cancer Research; Cardiology; Chronic exposure; Chronic obstructive pulmonary disease; Coronaviruses; COVID-19; Development and progression; Emphysema; Genotypes; Health aspects; Imipenem; Life Sciences; Lung diseases; Lungs; Medical Biochemistry; Microorganisms; Obstructive lung disease; Pandemics; Pathogenesis; Pathogens; Pirbuterol; Pseudomonas aeruginosa; Severe acute respiratory syndrome coronavirus 2; Synergistic effect; Ticarcillin; Viral diseases; COVID-19; Inflammation; Emphysema; Chronic bronchitis; Antibiotic resistance; COPD
• ISSN: 0300-8177; 1573-4919; 1573-4919
• DOI: 10.1007/s11010-023-04744-w

This article discusses the connection between the novel coronavirus disease 2019 (COVID-19) caused by the coronavirus-2 (SARS-CoV-2) and chronic obstructive pulmonary disease (COPD). COPD is a multifaceted respiratory illness that is typically observed in individuals with chronic exposure to chemical irritants or severe lung damage caused by various pathogens, including SARS-CoV-2 and Pseudomonas aeruginosa . The pathogenesis of COPD is complex, involving a variety of genotypes and phenotypic characteristics that result in severe co-infections and a poor prognosis if not properly managed. We focus on the role of SARS-CoV-2 infection in severe COPD exacerbations in connection to P.  aeruginosa infection, covering pathogenesis, diagnosis, and therapy. This review also includes a thorough structural overview of COPD and recent developments in understanding its complicated and chronic nature. While COVID-19 is clearly linked to emphysema and chronic bronchitis at different stages of the disease, our understanding of the precise interaction between microbial infections during COPD, particularly with SARS-CoV-2 in the lungs, remains inadequate. Therefore, it is crucial to understand the host–pathogen relationship from the clinician’s perspective in order to effectively manage COPD. This article aims to provide a comprehensive overview of the subject matter to assist clinicians in their efforts to improve the treatment and management of COPD, especially in light of the COVID-19 pandemic.